Loading...
XNASOTLK
Market cap55mUSD
Jan 03, Last price  
2.24USD
1D
8.74%
1Q
-57.17%
IPO
-59.42%
Name

Outlook Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:OTLK chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
119.30%
Rev. gr., 5y
9.32%
Revenues
0k
9,050,5425,219,2372,979,5763,811,5193,087,5608,146,1220000
Net income
-59m
L-10.70%
-13,732,473-47,393,283-53,329,262-38,849,127-46,114,924-34,523,787-35,239,000-53,163,000-66,052,264-58,982,668
CFO
-43m
L-24.18%
-7,020,469-27,476,200-45,482,672-15,505,0540-32,289,988-31,790,093-54,253,288-56,674,559-42,973,398
Earnings
Feb 12, 2025

Profile

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
URL
https://outlooktherapeutics.com/
IPO date
Jun 13, 2016
Employees
17
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
Cost of revenue
53,171
63,275
Unusual Expense (Income)
NOPBT
(53,171)
(63,275)
NOPBT Margin
Operating Taxes
3
3
Tax Rate
NOPAT
(53,173)
(63,278)
Net income
(58,983)
-10.70%
(66,052)
24.24%
Dividends
Dividend yield
Proceeds from repurchase of equity
30,024
62,307
BB yield
-1,086.08%
-481.63%
Debt
Debt current
35,555
10,954
Long-term debt
4
47
Deferred revenue
Other long-term liabilities
6
57
Net debt
11,374
(7,201)
Cash flow
Cash from operating activities
(42,973)
(56,675)
CAPEX
(2)
Cash from investing activities
Cash from financing activities
48,969
59,594
FCF
(51,782)
7,030,752,800
Balance
Cash
23,392
17,397
Long term investments
794
805
Excess cash
24,186
18,202
Stockholders' equity
(465,316)
28,527,762,010
Invested Capital
486,439
(307)
ROIC
ROCE
EV
Common stock shares outstanding
12,509
10,604
Price
0.22
-81.89%
1.22
-43.78%
Market cap
2,764
-78.63%
12,937
-21.90%
EV
14,138
28,527,756,736
EBITDA
(53,126)
(63,071)
EV/EBITDA
Interest
1,560
1,487
Interest/NOPBT